Royalty Pharma officer plans $644K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Royalty Pharma plc officer Terrance Coyne is named as the person for whose account 11,002 common shares are to be sold by TPC RP EPA1 LLC. The proposed sale is listed for August 13, 2026, at an aggregate market value of $644,277.12.
The shares were acquired from the issuer as compensation through performance awards on August 5, 2026. The sale is connected with a selling plan dated February 24, 2026, intended to comply with Rule 10b5-1(c). The past-three-months sales section lists TPC RP EPA1 LLC as selling 64,399 common shares on May 26, 2026, for gross proceeds of $3,476,118.96.
Key Figures
Key Terms
Rule 10b5-1(c) regulatory
Performance Awards financial
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.